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costs across hernia repair and mesh type cohorts are also presented. RESULTS:
Across treatment groups the majority of patients were white (70%) with a mean
age of 54 years. Inguinal and umbilical hernia repair groups were both predomi-
nantly male with low to moderate incidences of obesity and diabetes. Incisional
hernia repair patients had the highest incidence of obesity (19.0%) and diabetes
(18.5%) and could be equally either male (42.0%) or female (58.0%). Tissue-separat-
ing mesh (TSM) was used mainly in incisional hernia repairs, whilst other meshes
were used in all surgical cohorts. TSM was used more frequently in females (60.1%)
and in patients with a high incidence of obesity (22.7%) and diabetes (22.1%). No
striking differences in surgical costs across the hernia repair or mesh type cohorts
were observed, with average surgical costs between $2199 and $4099.
CONCLUSIONS: This is the first example of extracting hernia repair patient demo-
graphics from a nationwide database. Although there are limitations to the inter-
pretation of this data, these results are encouraging. Further development of the
management, analysis and interpretation of such data is ongoing.
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OBJECTIVES: Drug-eluting stents (DES) and bare-metal stents (BMS) are both used
widely in percutaneous coronary interventions (PCI). However, the incremental
cost-effectiveness of DES versus BMS varies considerably between studies. A sys-
tematic review is performed to gain insight how modeling influences the cost-
effectiveness of DES versus BMS. METHODS: We reviewed modeling studies pub-
lished until February 2011 that studied the cost-effectiveness of DES versus BMS.
We then extracted various parameters (e.g., model type, time horizon, data
sources, choice of disease states) and explored the influence of these parameters
on the cost-effectiveness outcomes. RESULTS: The incremental cost-effectiveness
ratios (ICER) from the 22 eligible studies ranged from DES being dominated by BMS
to DES being dominant. Different parameters can contribute to these differences,
including time horizon, assumptions concerning stent efficacy, study perspective,
stent cost prices and the specific type of stents being compared. Almost half of the
studies used a time horizon 12 months, assuming that differences in clinical
events between the two stents occur in the first year. However, published literature
contradicts this assumption since DES can induce very late in-stent thrombosis.
Moreover, many studies base restenosis rates on angiographic follow-up. Since
angiography overestimates the difference in restenosis rate between DES and BMS,
its use leads to an overestimate of quality-adjusted life-years gained and number of
avoided reinterventions and an underestimate of the costs of the DES strategy. The
price premium of DES versus BMS differs considerably between studies (€900-
€3300) and this difference also affects the ICER. CONCLUSIONS: Choices made in
cost-effectiveness models to compare DES with BMS lead to wide variation in cost-
effectiveness estimates, making it difficult to conclude that DES is more cost-effec-
tive than BMS. Since 80,000 PCIs are performed per year in the UK, it is very impor-
tant to obtain valid estimates of the cost-effectiveness of DES versus BMS.
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OBJECTIVES: Conventional balloon angioplasty for treatment of femoropopliteal
arterial disease is associated with a high restenosis rates 12 months post-proce-
dure. Recent clinical data have showed that use of DEBs may substantially reduce
restenosis. This suggests that DEB may decrease number of revascularizations and
therefore be a cost-effectiveness treatment for peripheral artery disease (PAD).
This study evaluated the economic impact of using a drug-eluting balloon (DEB) for
treatment of femoropoliteal arterial disease. METHODS: A decisional tree model
has been developed to compare two alternative treatment strategies for superficial
femoral artery disease (SFA): standard balloon angioplasty (PTA) and provisional
stenting versus DEB. Cost for initial hospital care and the long term management of
the disease, including reintervention, has been accounted for according to National
Health Care Service and societal perspectives. Probabilities have been retrieved by
available literature review of RCT and from an observational study on DEB that
evaluated risk of target lesion revascularization (TLR) at 1 year. Uncertainty around
the model inputs was tested using unvaried and multivariate sensitivity analyses
RESULTS: Specific procedure costs (including angioplasty balloon, DEB, stent, con-
trast medium) were 1500€ in both group because incremental cost for use of DEB
was offset by reduction of number of stents used in the DEB arm. No difference has
been noted also for initial hospitalization. Given a 1 year TLR rate of 8.7% and 14%
for DEB and stenting respectively, DEB resulted a cost-saving strategy for the treat-
ment of superficial femoral artery disease. Results were sensitive to hypothesis on
number of stents and DEB used and their relative cost. CONCLUSIONS: PTA of
femoropopliteal arterial disease using DEB appears to be a clinical improvement for
treatment of PAD and a potentially cost saving strategy compared to use of stents
in the Italian Health Care System.
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OBJECTIVES: Cost-effectiveness analysis (CEA) of a medical test can require exten-
sive modeling if test results influence treatment decisions and disease progression.
We applied the assessment hierarchy of Schaafsma et al. (2009) to a CEA of a high
definition CT-scanner (one of the first assessments in the NICE/UK Diagnostics
Guidance Programme). METHODS: Schaafsma presents four steps to evaluate the
value of diagnostic tests: 1:accuracy assessment, 2:evaluation of added value,
3:clinical outcome assessment and 4:cost-effectiveness analysis. RESULTS: In the
assessment of diagnostic tests in coronary artery disease (CAD) modeling was
unavoidable, since a major problem in CEAs is the unavailability of randomized
controlled trials (RCT) that capture diagnosis, prognosis and treatment. Moreover,
most RCTs in the field of diagnostic test yield only information about sensitivity,
specificity, and short-term complication rates. When the evaluation is limited to
the added value of the high definition CT-scanner, one model, estimating the pro-
portions correctly diagnosed and complications associated with the CT-scanner, is
sufficient. However, since incorrect test results can result in major health loss
through incorrect or delayed treatment this method is inappropriate. Most tests
aim to improve prognosis thus, step 3 and 4 were applied in our assessment. There-
fore, five existing models were combined (diagnosis, CAD management, stroke
complication, radiation, non-CAD mortality) to create a meta-model that estimates
the cost-effectiveness. CONCLUSIONS: CEAs of a medical test can be performed in
various ways described by Schaafsma. If the aim is to conduct a comprehensive
analysis that includes various economic and health impacts, a synthesis of existing
models to create a meta-model is one way to achieve this. These models need to be
grafted together carefully to avoid invalid or irrelevant results; literature and ex-
pert opinion can assist in that endeavour. One critical pitfall is the use of models
created for dissimilar patient populations.
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OBJECTIVES:Health care resources are scarce and decisions have to be made about
how to allocate funds. Often these decisions are based on sparse or imperfect
evidence. One such example is negative pressure wound therapy (NPWT), which is
a widely used treatment for severe pressure ulcers; however, there is currently no
robust evidence that it is effective or cost effective.METHODS: This work considers
the decision to adopt NPWT given a range of alternative treatments, using a deci-
sion analytic modelling approach. Literature searches were conducted to identify
existing evidence on model parameters. Given the limited evidence base, a second
source of evidence, beliefs elicited from experts, was used. Judgements from ex-
perts on relevant (uncertain) quantities were obtained through a formal elicitation
exercise. Additionally, data derived from a pilot trial were also used to inform the
model. The three sources of evidence were collated, and the impact of each on cost
effectiveness was evaluated. RESULTS: Negative pressure wound therapy was ex-
pected to be less costly and more effective than any other treatments. The decision
to adopt NPWT was however very uncertain (probability of being cost effective of
0.55). The expected value of perfect information for the relevant UK population was
approximately £98 million. Specifically, the results suggest that a study evaluating
the effectiveness of NPWT might be worthwhile. The trial design that offered most
value was a three armed trial, with follow-up of at least 1 year and approximately
500 participants per arm. CONCLUSIONS: The analyses presented demonstrate
how allocation decisions about medical technologies can be explicitly informed
when data are sparse and, how this kind of analyses can be used to guide future
research prioritisation, not only indicating whether further research is worthwhile
but what type of research is needed and how it should be designed.
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OBJECTIVES: Nighttime urinary frequency (nocturia), common in patients with
overactive bladder (OAB), negatively impacts sleep quality. Three sleep-related
patient-reported questionnaires were assessed with regard to ability to discrimi-
nate between patients with and without OAB. METHODS: Adult men and women
with OAB symptoms for at least 3 months (8 micturitions per day;2 micturitions
per night; and6 urgency episodes over 3 days per bladder diary) and without OAB
symptoms (control group) completed several sleep questionnaires: Stanford Sleep-
iness Scale (morning and evening for 5 days), Epworth Sleepiness Scale, and Noc-
turia Quality of Life Questionnaire (N-QoL); t tests were performed between groups.
RESULTS: A total of 43 participants with OAB and 10 healthy controls were en-
rolled. Mean age and proportion of men were similar in the OAB and control groups
(63.7 vs. 55.6 years old [P0.31], and 46.2% vs 40.0% male [P0.53], respectively).
Race, employment status, and education level were also similar between groups
(all P0.25). Mean scores on the Stanford Sleepiness Scale across the 5 days were
significantly higher in the OAB group than the control group at time of awakening
(3.0 vs. 2.0; P0.0030) and at 7:00 pm (3.5 vs. 1.9; P0.0006), indicating greater
sleepiness. Epworth Sleepiness Scale mean scores were also significantly higher in
the OAB group than the control group (10.5 vs 4.1, respectively; P0.0001), indicat-
ing greater daytime sleepiness. On the N-QoL, participants with OAB had signifi-
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